Navigating the Evolving Therapeutic Landscape in Advanced Prostate Cancer

Statement of Need and Purpose

The treatment of castration-resistant prostate cancer (CRPC) has undergone a rapid evolution over the last decade. Advances in understanding of the mechanisms of CRPC progression have highlighted several pathways and targets that appear promising to better treat this disease.  A number of new therapies from different therapeutic categories have demonstrated ability to improve survival in patients with advanced disease.  With all of these advances, it is challenging for clinicians to remain current on all the latest advances in the management of advanced prostate cancer, and they often have unanswered questions about the evidence and how to apply it in their practice.


Upon completion of the activities of this initiative, the participant should be better able to:

  • Assess the incidence of and clinical markers for classifying advanced prostate cancer (castration-resistant prostate cancer; CRPC);
  • Evaluate the importance of the prostate tumor microenvironment, including the role of the immune system,  and androgen receptor signaling;
  • Discuss current treatment approaches for CRPC, including challenges and limitations;
  • Assess strategies to integrate existing and new therapies into cancer clinical practice for the treatment of advanced prostate cancer.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The University of Cincinnati designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Date of Original Release/Review

This supplement was published in Urologic Oncology.  The original release date is May 24, 2017 and is eligible for AMA PRA Category 1 Credit™ through May 24, 2018.



Oliver Sartor, MD
C.E. & Bernadine Laborde Professor for Cancer Research,
Departments of Medicine and Urology
Medical Director, Tulane Cancer Center
New Orleans, LA

E. David Crawford, MD
Section of Urologic Oncology, School of Medicine,
University of Colorado
Denver, Aurora, CO


Daniel Petrylak, MD
Department of Medicine (Medical Oncology) and Urology
Yale (Smilow) Cancer Center
New Haven, CT

Disclosure of Conflicts of Interest

According to the disclosure policy of the University of Cincinnati College of Medicine, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with the commercial companies related to this activity.  All relevant relationships that are identified are reviewed for potential conflicts of interest. If a conflict of interest is identified, it is the responsibility of the University of Cincinnati College of Medicine to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.


Relationship Identified With:

Oliver Sartor, MD 

Consultant: Algeta, Amgen, Bayer, Bellicum, Bristol-Mayer Squibb, Celgene, Dendreon, Exelixis, GSK, Johnson & Johnson, Medivation, Oncogenex, Sanofi-Aventis

Grant/Research Support: Algeta, AstraZeneca, Cougar, GSK, Johnson & Johnson, sanofi-aventis

Owns Stock: GSK, Johnson & Johnson, Lilly

E David Crawford, MDL

Advisor: Bayer, MDxHealth

Speakers Bureau: Astellas

Daniel Petrylak, MD

Consultant: Bayer, Bellicum, Dendrion, Sanofi-Aventis, Johnson & Johnson, Enelixis, Ferring, Millenium, Medivation, Pfizer

Grant/Research Support: Oncogenix, Progenies, Johnson & Johnson, Millenium, Celgene, Dendreon, sanofi-aventis

The following reviewers/planners have reported real or apparent conflicts of interest:

  • Susan Tyler, MEd, CMP, CHCP, CME Director, has nothing to disclose
  • Rick E. Ricer, MD, Professor Emeritus, has nothing to disclose
  • Deborah Cole, BS, Program Coordinator, has nothing to disclose
  • Otto Ratz, MD, has nothing to disclose
  • Christina Culbert, MSc, has nothing to disclose


This CME activity was developed through the joint providership of the University of Cincinnati and CORE Medical Education, LLC.


Commercial Support

This supplement is supported by an educational grant from SAnofi US.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither the University of Cincinnati College of Medicine nor CORE Medical Education, LLC, recommends the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati College of Medicine or CORE Medical Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Instructions for Participation

The estimated time to complete is 60 minutes.  There are no fees for participating in and receiving CME credit for this activity.  Participants must 1) read the CME information, including the learning objectives and faculty disclosures; 2) read the full content of the activity and reflect upon its teachings; 3) successfully complete the post- test with a passing score of 70% and the evaluation online. For technical problems regarding this online CME activity, please contact

Review Process

The entire faculty discussed the content at a peer-review planning session; the chair reviewed the activity for accuracy and fair balance, and a member of the External CME Advisory Board, who is without conflict of interest, reviewed the activity to determine whether the material is evidence-based, objective and demonstrated fair balance.


This Supplement is derived from a planning teleconference series which was held between 11/01/2015 and 12/22/2015 and was independently developed by the University of Cincinnati College of Medicine and CORE Medical Education LLC, pursuant to an educational grant from sanofi-aventis U.S. The opinions expressed herein are those of the faculty and do not necessarily reflect the opinions of the CME provider and publisher, or the commercial supporter.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedure, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without the evaluation of their patients’ conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 3.00 AMA PRA Category 1 Credit(s)™
  • 3.00 Non-physician
Course opens: 
Course expires: 

Available Credit

  • 3.00 AMA PRA Category 1 Credit(s)™
  • 3.00 Non-physician
Please login or register to take this course.